HASTINGS PAUL J — SEC insider filings
SEC reporting owner CIK 1309702. 34 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2021-01-12 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 24 legs across 19 filings — 140,475 shares, $2,201,306 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 11,461 shares @ $30.23 ($346,466) in Nkarta, Inc., filed 2021-04-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | Chief Executive Officer, Director | 21 | — | 18 legs · 127,852 sh · $1,593,971 | 16 |
| Pacira BioSciences, Inc. (PCRX) | Director | 9 | — | 6 legs · 12,623 sh · $607,335 | 12 |
| enGene Therapeutics Inc. (ENGN) | Director | 3 | — | — | 3 |
| Azora Therapeutics, Inc. (DE) (AZR) | Director | 1 | — | — | — |
Insider filings — HASTINGS PAUL J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 3 | Azora Therapeutics, Inc. (DE) (AZR) | Holdings only — no transactions reported | EDGAR |
| 2026-06-22 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,776 @ $2.71 | EDGAR |
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 26,046 @ $2.07 | EDGAR |
| 2026-01-08 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 94,000 @ $0 · Grant/award (A): 562,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,790 @ $1.79 | EDGAR |
| 2025-06-16 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 377,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 17,378 @ $2.20 | EDGAR |
| 2025-01-07 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 94,500 @ $0 · Grant/award (A): 565,500 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,770 @ $5.60 | EDGAR |
| 2024-06-18 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 5,230 @ $0 · Sale (S): 880 @ $28.38 · Grant/award (A): 12,179 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Nkarta, Inc. (NKTX) | Disposition to issuer (D): 12,358 @ $13 · Disposition to issuer (D): 137,642 @ $13.33 | EDGAR |
| 2024-01-18 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 9,697 @ $8.74 | EDGAR |
| 2024-01-08 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 85,000 @ $0 · Grant/award (A): 509,500 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 1,704 @ $4.85 | EDGAR |
| 2023-06-16 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,775 @ $0 · Grant/award (A): 12,925 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | Pacira BioSciences, Inc. (PCRX) | Sale (S): 580 @ $38.34 | EDGAR |
| 2023-05-17 | 4 | Pacira BioSciences, Inc. (PCRX) | Option exercise (M): 7,000 @ $29.90 · Sale (S): 7,000 @ $41.85 · Option exercise (M): 7,000 (derivative) @ $0 | EDGAR |
| 2023-01-18 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 64,500 @ $0 · Sale (S): 3,691 @ $5.49 · Grant/award (A): 386,500 (derivative) @ $0 | EDGAR |
| 2022-09-30 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 23,376 @ $13.03 · Sale (S): 498 @ $13 | EDGAR |
| 2022-09-22 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 6,126 @ $13.01 | EDGAR |
| 2022-07-13 | 4 | Pacira BioSciences, Inc. (PCRX) | Sale (S): 533 @ $56.95 | EDGAR |
| 2022-06-21 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 19,500 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2022-06-08 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,160 @ $0 · Grant/award (A): 8,225 (derivative) @ $0 | EDGAR |
| 2022-01-19 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 41,900 @ $0 · Grant/award (A): 251,100 (derivative) @ $0 | EDGAR |
| 2021-10-01 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 8,277 @ $27.20 · Sale (S): 223 @ $26.53 | EDGAR |
| 2021-06-23 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 4,693 @ $26.39 · Sale (S): 3,807 @ $26.89 | EDGAR |
| 2021-06-11 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,066 @ $0 · Grant/award (A): 7,626 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Pacira BioSciences, Inc. (PCRX) | Sale (S): 630 @ $62.19 | EDGAR |
| 2021-04-01 | 4 | Nkarta, Inc. (NKTX) | Sale (S): 11,461 @ $30.23 · Sale (S): 2,409 @ $31.24 · Sale (S): 3,130 @ $32.21 | EDGAR |
| 2021-03-09 | 4 | Pacira BioSciences, Inc. (PCRX) | Option exercise (M): 3,000 @ $13.98 · Sale (S): 3,000 @ $65.88 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 157,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1309702 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs